Background. New cancer biomarkers are being discovered at a rapid pace; however, these
tests vary in their predictive performance characteristics, and it is unclear how best to use …

Use of serum prostate-specific antigen (PSA) testing for early detection of prostate cancer
appears to reduce cancer-specific mortality. Due to the limited specificity of PSA for clinically …

Simple Summary PCa remains a leading health concern worldwide. Serum PSA-based PCa
screening led to a well-documented decreased mortality but at the cost of the increased …

Objective To assess the cost‐effectiveness of a new urinary biomarker‐based risk score
(Select MD x; MD xHealth, Inc., Irvine, CA, USA) to identify patients for transrectal …

Introduction Management of prostate cancer was revolutionized by the discovery of prostate
specific antigen. While prostate specific antigen is an excellent biomarker for followup after …

Active surveillance (AS) is now an accepted management strategy for men with low‐risk
localized prostate cancer (PCa). However, detecting disease progression in a patient …

Prostate cancer screening and diagnosis has been guided by prostate-specific antigen
levels for the past 25 years, but with the most recent US Preventive Services Task Force …

Purpose: Prostate cancer aggressiveness and appropriate therapy are routinely determined
following biopsy sampling. Current clinical and pathologic parameters are insufficient for …

Abstract Background. Many patients with Gleason 3+ 3 and 3+ 4 early stage prostate cancer
receive invasive treatment but likely derive little or no benefit. A novel 8-protein prognostic …

Prostate cancer is among the most commonly diagnosed cancers in men worldwide,
underscoring the necessity of effective screening tools for early detection and mortality …